Jan Gerard Sterrenburg

This inventor holds 10 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Netherlands Translational Research Center B.v., Merck Sharp + Dohme B.v.. Active years: 2017-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jan Gerard Sterrenburg. Retrieved from https://idiyas.com/inventor/jan-gerard-sterrenburg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 10 (Patent Applications = 4)

% Patents Active = 90.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 8)

Average Co-Inventor Count = 7.3

ph-index = 3

Forward Citations = 17(Granted Patents)

Location History:

TE Renkum, NL (2019)
Renkum, NL (2017 - 2021)
Oss, NL (2018 - 2024)

Company Filing History:

6 out of 8

Netherlands Translational Research Center B.v.

patents

4 out of 55

Merck Sharp + Dohme B.v.

patents

Years Active: 2017-2024

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE50082 - (5,6-dihydro)pyrimido[4,5-e]indolizines (2024-08-20),

2. RE48974 - (5,6-dihydro)pyrimido[4,5-E]indolizines (2022-03-14),

3. 11053230 - 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase (2021-07-06),

4. 10934296 - 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors (2021-03-02),

5. 10689343 - Inhibitors of tryptophan 2,3-dioxygenase (2020-06-23),

6. 10494360 - Inhibitors of indoleamine 2,3-dioxygenase (2019-12-03),

7. 10239883 - 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors (2019-03-26),

8. 9856258 - (5,6-dihydro)pyrimido[4,5-E]indolizines (2018-01-02),

9. 9790226 - 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as BtK inhibitors (2017-10-17),

10. 9758524 - 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors (2017-09-12),

Title: The Innovative Mind of Jan Gerard Sterrenburg

Introduction

Jan Gerard Sterrenburg, hailing from Renkum, Netherlands, is a noteworthy inventor credited with an impressive portfolio of 10 patents. His inventions primarily focus on pharmaceutical compositions aimed at combating cancer, showcasing his commitment to advancing medical science and enhancing patient outcomes.

Latest Patents

Among his recent innovations are compounds identified as (5,6-dihydro)pyrimido[4,5-e]indolizines. These compounds, specified by a unique formula, include R and R that can be independently selected from a variety of optionally substituted (6-10 carbon) aryl and (1-5 carbon) heteroaryl groups. Notably, these compounds have significant potential in pharmaceutical compositions, particularly for cancer treatment.

Career Highlights

Jan has made significant contributions through his roles in esteemed organizations such as Netherlands Translational Research Center B.V. and Merck Sharp & Dohme B.V. His work in these companies has paved the way for new therapeutic approaches in the medical field.

Collaborations

Throughout his career, Jan Gerard Sterrenburg has collaborated with other talented individuals, including Adrianus Petrus Antonius De Man and Joost Cornelis Marinus Uitdehaag. These partnerships have amplified his innovative capabilities and have potentially led to groundbreaking advancements in pharmaceuticals.

Conclusion

Jan Gerard Sterrenburg's dedication to exploration and innovation in the field of pharmaceutical inventions is commendable. As an inventor, he continues to influence the healthcare landscape, offering hope through his research and discoveries. His ongoing contributions exemplify the critical role inventors play in the advancement of science and technology.

Profile summary based on public USPTO records.